<ul>
<li>現在值得購買的三大醫療設備股票</li>
</ul>
<p>Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO - 免費報告）- Zacks Research 在 9 月 22 日（星期一）發佈的報告中下調了對 Bio-Rad Laboratories 2026 財年每股收益（EPS）的預期。Zacks Research 分析師團隊現在預計該醫療研究公司將發佈 10.36 美元的每股收益，低於之前預測的 10.43 美元。Zacks Research 對該股票給予了 “持有” 評級。市場普遍預計 Bio-Rad Laboratories 當前全年的每股收益為 10.81 美元。Zacks Research 還對 Bio-Rad Laboratories 2026 年第四季度的每股收益進行了預測，預計為 2.62 美元。</p>
<p>獲取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
<p>BIO 在其他幾份研究報告中也成為了話題。富國銀行將 Bio-Rad Laboratories 的目標股價從 245.00 美元上調至 265.00 美元，並在 8 月 1 日（星期五）的報告中給予該股票 “等權重” 評級。加拿大皇家銀行將 Bio-Rad Laboratories 的目標股價從 387.00 美元上調至 409.00 美元，並在 8 月 1 日（星期五）的研究報告中給予該股票 “跑贏大盤” 評級。最後，華爾街 Zen 在 8 月 22 日（星期五）的報告中將 Bio-Rad Laboratories 的評級從 “買入” 下調至 “持有”。三位分析師對該股票給予了 “買入” 評級，兩位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 333.50 美元。</p>
<p><strong>閲讀我們關於 BIO 的最新股票報告</strong></p>
<h2>Bio-Rad Laboratories 股票表現</h2>
<p>Bio-Rad Laboratories 的股票在星期二開盤價為 283.63 美元。Bio-Rad Laboratories 的 1 年最低價為 211.43 美元，1 年最高價為 387.99 美元。該公司的流動比率為 5.12，速動比率為 3.67，債務與股本比率為 0.17。該公司的市值為 76.8 億美元，市盈率為 24.18，貝塔值為 0.95。該公司的 50 日簡單移動平均線為 275.86 美元，200 日簡單移動平均線為 252.83 美元。</p>
<p>Bio-Rad Laboratories（紐約證券交易所代碼：BIO - 獲取免費報告）最近於 7 月 31 日（星期四）公佈了季度財報。該醫療研究公司報告的季度每股收益為 2.61 美元，超出分析師一致預期的 1.93 美元，超出幅度為 0.68 美元。該公司季度收入為 6.516 億美元，而市場普遍預期為 6.1482 億美元。Bio-Rad Laboratories 的淨利潤率為 12.50%，股本回報率為 4.01%。該公司季度收入同比增長 2.1%。在去年同期，該公司每股收益為 3.11 美元。Bio-Rad Laboratories 已設定 2025 財年的每股收益指導。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金最近對該公司的持倉進行了調整。Nuveen Asset Management LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 0.8%。Nuveen Asset Management LLC 目前擁有 39,505 股該醫療研究公司的股票，價值為 12,978,000 美元，在此期間又購買了 327 股。ProShare Advisors LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 8.0%。ProShare Advisors LLC 目前擁有 901 股該醫療研究公司的股票，價值為 296,000 美元，在上個季度又收購了 67 股。Tidal Investments LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 21.1%。Tidal Investments LLC 目前擁有 1,069 股該醫療研究公司的股票，價值為 351,000 美元，在上個季度又收購了 186 股。Two Sigma Investments LP 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 70.3%。Two Sigma Investments LP 目前擁有 2,050 股該醫療研究公司的股票，價值為 673,000 美元，在此期間又購買了 846 股。最後，俄亥俄州公共僱員退休系統在第四季度購買了 Bio-Rad Laboratories 的新股份，價值約為 2,211,000 美元。65.24% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Bio-Rad Laboratories</h2>
<p>（獲取免費報告）</p>
<p>Bio-Rad Laboratories, Inc.在美國、歐洲、亞洲、加拿大和拉丁美洲製造和分銷生命科學研究和臨牀診斷產品。它通過生命科學和臨牀診斷兩個部門運營。該公司開發、製造和銷售儀器、系統、試劑和耗材，以分離、純化、表徵和定量生物材料，如細胞、蛋白質和核酸，應用於蛋白質組學、基因組學、生物製藥生產、細胞生物學和食品安全市場。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Bio-Rad Laboratories</li>
<li>如何投資 FAANG 股票</li>
<li>弱美元如何推動這些全球股票的上漲</li>
<li>如何計算期權利潤</li>
<li>3 只在經濟放緩時表現良好的股票</li>
<li>10 美元以下的最佳股票</li>
<li>3 只被低估的自動化股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bio-Rad Laboratories 嗎？</h2>
<p>在你考慮 Bio-Rad Laboratories 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bio-Rad Laboratories 並不在名單上。</p>
<p>雖然 Bio-Rad 實驗室目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Bio-Rad實驗室-A

<p>Zacks Research 將 Bio-Rad Laboratories (NYSE:BIO) 的 2026 財年每股收益 (EPS) 預估從 $10.43 下調至 $10.36。該公司全年收益的當前共識預估為每股 $10.81。Zacks 對該股票維持 “持有” 評級，而富國銀行和加拿大皇家銀行則提高了其目標股價。Bio-Rad 的股票開盤價為 $283.63，市值為 76.8 億美元，市盈率為 24.18。最近的季度收益超出預期，報告每股收益為 $2.61，超過共識預期的 $1.93</p>

<ul>
<li>The Top 3 Medical Devices Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在值得購買的三大醫療設備股票</li>
</ul>
</div><p>Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report released on Monday, September 22nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $10.36 for the year, down from their previous forecast of $10.43. Zacks Research has a &#34;Hold&#34; rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2026 earnings at $2.62 EPS.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO - 免費報告）- Zacks Research 在 9 月 22 日（星期一）發佈的報告中下調了對 Bio-Rad Laboratories 2026 財年每股收益（EPS）的預期。Zacks Research 分析師團隊現在預計該醫療研究公司將發佈 10.36 美元的每股收益，低於之前預測的 10.43 美元。Zacks Research 對該股票給予了 “持有” 評級。市場普遍預計 Bio-Rad Laboratories 當前全年的每股收益為 10.81 美元。Zacks Research 還對 Bio-Rad Laboratories 2026 年第四季度的每股收益進行了預測，預計為 2.62 美元。</p>
</div><p>Get <strong>Bio-Rad Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
</div><p>BIO has been the topic of several other research reports. Wells Fargo &amp; Company upped their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, August 1st. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, August 1st. Finally, Wall Street Zen cut Bio-Rad Laboratories from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $333.50.</p>
<div class="lb-trans"><p>BIO 在其他幾份研究報告中也成為了話題。富國銀行將 Bio-Rad Laboratories 的目標股價從 245.00 美元上調至 265.00 美元，並在 8 月 1 日（星期五）的報告中給予該股票 “等權重” 評級。加拿大皇家銀行將 Bio-Rad Laboratories 的目標股價從 387.00 美元上調至 409.00 美元，並在 8 月 1 日（星期五）的研究報告中給予該股票 “跑贏大盤” 評級。最後，華爾街 Zen 在 8 月 22 日（星期五）的報告中將 Bio-Rad Laboratories 的評級從 “買入” 下調至 “持有”。三位分析師對該股票給予了 “買入” 評級，兩位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 333.50 美元。</p>
</div><p><strong>Read Our Latest Stock Report on BIO</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 BIO 的最新股票報告</strong></p>
</div><h2>Bio-Rad Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>Bio-Rad Laboratories 股票表現</h2>
</div><p>Bio-Rad Laboratories stock opened at $283.63 on Tuesday. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $7.68 billion, a PE ratio of 24.18 and a beta of 0.95. The firm's 50 day simple moving average is $275.86 and its 200 day simple moving average is $252.83.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories 的股票在星期二開盤價為 283.63 美元。Bio-Rad Laboratories 的 1 年最低價為 211.43 美元，1 年最高價為 387.99 美元。該公司的流動比率為 5.12，速動比率為 3.67，債務與股本比率為 0.17。該公司的市值為 76.8 億美元，市盈率為 24.18，貝塔值為 0.95。該公司的 50 日簡單移動平均線為 275.86 美元，200 日簡單移動平均線為 252.83 美元。</p>
</div><p>Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories（紐約證券交易所代碼：BIO - 獲取免費報告）最近於 7 月 31 日（星期四）公佈了季度財報。該醫療研究公司報告的季度每股收益為 2.61 美元，超出分析師一致預期的 1.93 美元，超出幅度為 0.68 美元。該公司季度收入為 6.516 億美元，而市場普遍預期為 6.1482 億美元。Bio-Rad Laboratories 的淨利潤率為 12.50%，股本回報率為 4.01%。該公司季度收入同比增長 2.1%。在去年同期，該公司每股收益為 3.11 美元。Bio-Rad Laboratories 已設定 2025 財年的每股收益指導。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its position in Bio-Rad Laboratories by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company's stock valued at $12,978,000 after buying an additional 327 shares during the period. ProShare Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after acquiring an additional 67 shares during the last quarter. Tidal Investments LLC raised its stake in shares of Bio-Rad Laboratories by 21.1% during the fourth quarter. Tidal Investments LLC now owns 1,069 shares of the medical research company's stock valued at $351,000 after acquiring an additional 186 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Bio-Rad Laboratories by 70.3% during the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock worth $673,000 after purchasing an additional 846 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $2,211,000. 65.24% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。Nuveen Asset Management LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 0.8%。Nuveen Asset Management LLC 目前擁有 39,505 股該醫療研究公司的股票，價值為 12,978,000 美元，在此期間又購買了 327 股。ProShare Advisors LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 8.0%。ProShare Advisors LLC 目前擁有 901 股該醫療研究公司的股票，價值為 296,000 美元，在上個季度又收購了 67 股。Tidal Investments LLC 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 21.1%。Tidal Investments LLC 目前擁有 1,069 股該醫療研究公司的股票，價值為 351,000 美元，在上個季度又收購了 186 股。Two Sigma Investments LP 在第四季度將其在 Bio-Rad Laboratories 的持倉增加了 70.3%。Two Sigma Investments LP 目前擁有 2,050 股該醫療研究公司的股票，價值為 673,000 美元，在此期間又購買了 846 股。最後，俄亥俄州公共僱員退休系統在第四季度購買了 Bio-Rad Laboratories 的新股份，價值約為 2,211,000 美元。65.24% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Bio-Rad Laboratories</h2>
<div class="lb-trans"><h2>關於 Bio-Rad Laboratories</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.在美國、歐洲、亞洲、加拿大和拉丁美洲製造和分銷生命科學研究和臨牀診斷產品。它通過生命科學和臨牀診斷兩個部門運營。該公司開發、製造和銷售儀器、系統、試劑和耗材，以分離、純化、表徵和定量生物材料，如細胞、蛋白質和核酸，應用於蛋白質組學、基因組學、生物製藥生產、細胞生物學和食品安全市場。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Bio-Rad Laboratories</li>
<li>How to Invest in the FAANG Stocks</li>
<li>How The Weak Dollar Is Fueling These Global Stock Surges</li>
<li>How to Calculate Options Profits</li>
<li>3 Recession-Ready Stocks That Thrive When the Economy Sputters</li>
<li>Best Stocks Under $10.00</li>
<li>3 Automation-Focused Stocks Flying Under the Radar</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Bio-Rad Laboratories</li>
<li>如何投資 FAANG 股票</li>
<li>弱美元如何推動這些全球股票的上漲</li>
<li>如何計算期權利潤</li>
<li>3 只在經濟放緩時表現良好的股票</li>
<li>10 美元以下的最佳股票</li>
<li>3 只被低估的自動化股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Rad Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bio-Rad Laboratories 嗎？</h2>
</div><p>Before you consider Bio-Rad Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bio-Rad Laboratories 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bio-Rad Laboratories 並不在名單上。</p>
</div><p>While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bio-Rad 實驗室目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Zacks 研究對 Bio-Rad Lab 2026 財年收益的預測是什麼？